Today's Date: June 4, 2023
Statement by the Prime Minister on Canadian Armed Forces Day   •   Reigniting the Cancer Moonshot: Massive Bio Joins CancerX as Founding Member to Accelerate Innovation and AI Implementation in C   •   Government of Canada releases summary of actions taken to address the safety and wellbeing of Indigenous women, girls and 2SLGBT   •   Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipili   •   Cupshe Celebrates 8th Birthday with Exclusive Collection in Collaboration with Chanel Iman, Heather Rae El Moussa, and Brittany   •   ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Pl   •   New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing   •   Research Results from Ontada HOPE Studies Presented at ASCO 2023 Illuminate How Social Determinants of Health Impact Different P   •   Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclit   •   Air Canada's Inaugural Amsterdam-Montreal Route Takes Off; Uplifts Sustainable Aviation Fuel in Amsterdam   •   High Schooler empowers Youth with Nonprofit "Unlimited Potential", raises $100,000 for Sports Medicine Research and Advocacy   •   Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y   •   Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023   •   Statement by the Prime Minister to mark four years since the publication of the final report of the National Inquiry into Missin   •   Dorsett Wanchai Marks World Environment Day 2023 with Bold Paperless and Plastic-Free Sustainability Initiatives   •   Tips for a smooth transition to senior living from the San Luis Obispo assisted living professionals   •   TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years   •   Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Developme   •   Bijou Ikli named new CEO by Florida Assisted Living Association   •   GRAIL Presents Real-World Experience With The Galleri® Multi-Cancer Early Detection Test At 2023 ASCO Annual Meeting
Bookmark and Share

Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors

CAMBRIDGE, Mass. , March 21 /Businesswire/ - NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that Axel Hoos, MD, PhD, has joined the NextPoint Board of Directors. Dr. Hoos currently serves as the Chief Executive Officer of Scorpion Therapeutics and brings a wealth of business, entrepreneurial and biopharmaceutical research and development expertise to the role.

“Dr. Hoos is a recognized pioneer in immuno-oncology and has shaped the checkpoint therapeutic landscape through his work on a new development paradigm for IO medicines and the development of the anti-CTLA-4 antibody ipilimumab, the first FDA-approved checkpoint immunotherapy,” commented Detlev Biniszkiewicz, PhD, CEO of NextPoint Therapeutics. “Our team will benefit greatly from Dr. Hoos’ expertise and perspective as we advance our novel immuno-oncology programs targeting the HHLA2 pathway to the clinic.”

“Immuno-oncology has become a critical component in our treatment armamentarium for cancer patients, and scientists are seeking the next breakthrough medicine to further expand its reach. I am looking forward to working with the executive team and fellow Board members to help NextPoint realize its promise to deliver the next IO breakthrough,” said Dr. Hoos. “NextPoint's work on the HHLA2 pathway has the potential to expand the reach of precision immuno-oncology to a range of patients who do not benefit from currently available therapies.”

Prior to becoming CEO of Scorpion, Dr. Hoos served as Senior Vice President, R&D Governance Chair, and Therapeutic Area Head for Oncology at GlaxoSmithKline Pharmaceuticals (GSK). In that role, Dr. Hoos built the Oncology business across all therapeutic modalities in the focus areas of immuno-oncology, synthetic lethality, tumor cell targeting, epigenetics, and cell & gene therapy. He is a member of the Board of Trustees at the Sabin Vaccine Institute, Director on the Board of TCR2, and member of the Scientific Advisory Board and Co-Director of the Cancer Immunotherapy Consortium at the Cancer Research Institute. Dr. Hoos received his MD in Medicine from Heidelberg University, and his PhD in Molecular Oncology from the German Cancer Research Center. He trained in general surgery at the Technical University of Munich and as a fellow in cancer research at Memorial Sloan-Kettering Cancer Center.

About NextPoint Therapeutics

NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. To learn more, visit

STORY TAGS: United States, North America, Oncology, Health, Infectious Diseases, Research, Science, Pharmaceutical, Biotechnology, Massachusetts, Personnel,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News